Stock-Drop Suit Claims Against Drug Maker Dismissed; Class Certification Denied

Mealey's (September 25, 2019, 3:58 PM EDT) -- BOSTON — A federal judge in Massachusetts on Sept. 23 ruled that a lead plaintiff in a securities class action lawsuit against a drug company and certain of its current and former senior executives failed to sufficiently establish the necessary causal link between the defendants’ alleged misrepresentations during the class period and any claimed economic loss by the lead plaintiff to support his federal securities law claims (Tim Karth v. Keryx Biopharmaceuticals Inc., et al., No. 16-11745, D. Mass., 2019 U.S. Dist. LEXIS 161626)....